Edition:
India

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

6,393JPY
11:29am IST
Change (% chg)

¥-27 (-0.42%)
Prev Close
¥6,420
Open
¥6,370
Day's High
¥6,424
Day's Low
¥6,370
Volume
415,700
Avg. Vol
1,003,850
52-wk High
¥7,148
52-wk Low
¥5,496

Chart for

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)

Overall

Beta: 0.68
Market Cap(Mil.): ¥1,746,483.00
Shares Outstanding(Mil.): 296.57
Dividend: 80.00
Yield (%): 2.55

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

BRIEF-Morphotek Announces FDA Acceptance Of IND For Cancer Treatment

* MORPHOTEK ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR NEXT-GENERATION FARLETUZUMAB ANTIBODY-DRUG CONJUGATE MORAB-202

10 Jan 2018

BRIEF-Eisai, Merck Receive Breakthrough Therapy Designation From FDA For Lenvima, Keytruda

* EISAI AND MERCK RECEIVE BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR LENVIMA® (LENVATINIB MESYLATE) AND KEYTRUDA® (PEMBROLIZUMAB) AS COMBINATION THERAPY FOR ADVANCED AND/OR METASTATIC RENAL CELL CARCINOMA

09 Jan 2018

BRIEF-Eisai Co to invest about $8.8 mln at Vizag plant in India - Nikkei‍​

* Eisai co to invest about $8.8 million to install manufacturing equipment at Vizag plant in India - Nikkei‍​ Source text for Eikon: Further company coverage:

01 Nov 2017

BRIEF-Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

* Biogen and Eisai expand existing collaboration agreement to develop and commercialize investigational Alzheimer's disease treatments including phase 3 aducanumab

23 Oct 2017

BRIEF-Eisai Co signs agreement with Grupo Biotoscana granting GBT exclusive licensing rights

* Eisai Co - signed agreement with Grupo Biotoscana granting GBT exclusive licensing rights

03 Oct 2017

BRIEF-FDA approves Eisai's Fycompa for use as monotherapy for the treatment of partial-onset seizures

* FDA approves Eisai's Fycompa® (perampanel) for use as monotherapy for the treatment of partial-onset seizures

27 Jul 2017

BRIEF-Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma

* Eisai submits supplemental new drug application to FDA for lenvatinib in first-line hepatocellular carcinoma

25 Jul 2017

Earnings vs. Estimates